HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kronenberg, F. Articles by Dieplinger, H. Search for Related Content PubMed PubMed Citation Articles by Kronenberg, F. Articles by Dieplinger, H. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol 38, 1755-1763, Copyright © 1997 by Lipid Research, Inc.

ARTICLES

Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation

F Kronenberg, E Trenkwalder, A Lingenhel, G Friedrich, K Lhotta, M Schober, N Moes, P Konig, G Utermann and H Dieplinger
Institute of Medical Biology and Human Genetics, University of Innsbruck, Austria.

High plasma concentrations of lipoprotein[a] (Lp[a]) are considered a genetically determined risk factor for atherosclerosis. Lp[a] is produced by the liver. The site(s) and mechanism(s) of catabolism are presently unclear. Lp[a] is elevated secondary to end-stage renal disease which suggests a direct or indirect role of the kidney in the metabolism of Lp[a]. We therefore investigated, by a simple in vivo approach, whether Lp[a] is removed by the human kidney. Lp[a] plasma concentrations were measured simultaneously by various methods in the ascending aorta and renal vein of 100 patients undergoing coronary angiography or coronary angioplasty. Lp[a] levels differed significantly between the two vessels even after correcting for hemoconcentration (20.1 +/- 21.6 mg/dL versus 18.7 +/- 20.3 mg/dL, P < 0.001). This corresponds to a mean arteriovenous difference of -1.4 mg/ dL or -9% of the arterial concentration. No Lp[a] or intact apo[a] could be detected in urine from healthy probands. Although we cannot assign the kidney a regulatory role for Lp[a] plasma levels in humans with normal renal function, we conclude from our data that substantial amounts of this atherogenic lipoprotein are taken up by the kidney. The underlying mechanisms are unknown at the moment. This study therefore demonstrates for the first time that the human kidney plays an active role in the catabolism of Lp[a]. This may explain the elevated Lp[a] concentrations found in patients with chronic renal insufficiency.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				W. J. Cain, J. S. Millar, A. S. Himebauch, U. J. F. Tietge, C. Maugeais, D. Usher, and D. J. Rader Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a] J. Lipid Res., December 1, 2005; 46(12): 2681 - 2691. [Abstract] [Full Text] [PDF]

				D. S. Parsons, D. A. Reaveley, D. V. Pavitt, M. Misra, and E. A. Brown Lipoprotein (a) levels in those with high molecular weight apo (a) isoforms may remain low in a significant proportion of patients with end-stage renal disease Nephrol. Dial. Transplant., September 1, 2003; 18(9): 1848 - 1853. [Abstract] [Full Text] [PDF]

				E. Cauza, J. Kletzmaier, G. Bodlaj, A. Dunky, W. Herrmann, and K. Kostner Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function Nephrol. Dial. Transplant., August 1, 2003; 18(8): 1568 - 1572. [Abstract] [Full Text] [PDF]

				E. Cauza, J. Kletzmaier, G. Bodlaj, A. Dunky, W. Herrmann, and K. Kostner Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function Nephrol. Dial. Transplant., August 1, 2003; 18(88): 1568 - 1572. [Abstract] [Full Text]

				S. Gonbert, B. Saint-Jore, P. Giral, C. Doucet, J. Chapman, and J. Thillet Molecular Analysis of Apo(a) Fragmentation in Polygenic Hypercholesterolemia: Characterization of a New Plasma Fragment Pattern Arterioscler. Thromb. Vasc. Biol., August 1, 2001; 21(8): 1353 - 1358. [Abstract] [Full Text] [PDF]

				F. WAHN, V. DANIEL, F. KRONENBERG, G. OPELZ, D. V. MICHALK, and U. QUERFELD Impact of Apolipoprotein(a) Phenotypes on Long-Term Renal Transplant Survival J. Am. Soc. Nephrol., May 1, 2001; 12(5): 1052 - 1058. [Abstract] [Full Text]

				J. Fan, M. Challah, H. Shimoyamada, M. Shiomi, S. Marcovina, and T. Watanabe Defects of the LDL receptor in WHHL transgenic rabbits lead to a marked accumulation of plasma lipoprotein[a] J. Lipid Res., June 1, 2000; 41(6): 1004 - 1012. [Abstract] [Full Text]

				C. DOUCET, V. MOOSER, S. GONBERT, F. RAYMOND, J. CHAPMAN, C. JACOBS, and J. THILLET Lipoprotein(a) in the Nephrotic Syndrome: Molecular Analysis ofLipoprotein(a) and Apolipoprotein(a) Fragments in Plasma and Urine J. Am. Soc. Nephrol., March 1, 2000; 11(3): 507 - 513. [Abstract] [Full Text] [PDF]

				F. KRONENBERG, E. KUEN, E. RITZ, R. JUNKER, P. KÖNIG, G. KRAATZ, K. LHOTTA, J. F. E. MANN, G. A. MÜLLER, U. NEYER, et al. Lipoprotein(a) Serum Concentrations and Apolipoprotein(a) Phenotypes in Mild and Moderate Renal Failure J. Am. Soc. Nephrol., January 1, 2000; 11(1): 105 - 115. [Abstract] [Full Text]

				A. Niemeier, T. Willnow, H. Dieplinger, C. Jacobsen, N. Meyer, J. Hilpert, and U. Beisiegel Identification of Megalin/gp330 as a Receptor for Lipoprotein(a) In Vitro Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 552 - 561. [Abstract] [Full Text] [PDF]